The liver is the only organ in the human body that can regrow itself after a surgeon cuts part of it away, and Mayo Clinic doctors just found a hidden reason why that works for some patients but not others.
Story Snapshot
- Mayo Clinic researchers identified blood coagulation as a key driver behind the liver’s ability to regenerate after surgery.
- Dr. Patrick Starlinger and his team studied tissue samples from both healthy patients and those with liver disease to track the process.
- Some patients experience failed or delayed regeneration, which can lead to a dangerous condition called post-hepatectomy liver failure.
- A related Mayo-led trial found a common clotting drug cut the odds of this liver failure by roughly three times.
Why The Liver’s Comeback Matters To Patients
Surgeons remove part of the liver to treat cancer, tumors, and other serious diseases every year. The remaining liver tissue, called the remnant, has to grow back fast enough to keep the body running. When that process stalls, patients can face liver failure, a complication that carries a real risk of death. Understanding why regeneration succeeds or fails has been a medical mystery for decades.
Dr. Patrick Starlinger, a hepatobiliary and pancreas surgeon at Mayo Clinic Comprehensive Cancer Center, led research digging into that mystery. His team discovered that the blood coagulation system, the process that normally stops bleeding, plays a crucial role in triggering liver regrowth. “We were able to discover that the blood coagulation system is crucially important to allow these mechanisms of liver regeneration to actually occur,” Starlinger said.
How Researchers Tracked The Regrowth Process
The team analyzed liver samples from patients with healthy livers and compared them to samples from patients with liver disease. By studying how genes switch on and off during recovery, researchers mapped out what a successful regeneration looks like at the cellular level. Blood and tissue samples from over a hundred surgery patients helped the team tell the difference between livers that healed well and livers that struggled.
That distinction matters because doctors currently lean on imaging scans to estimate how much liver volume remains after surgery. Volume alone does not guarantee the remnant will function properly. A liver can look big enough on a scan and still fail to do its job, which is why surgeons also weigh blood flow, disease severity, and how much tissue was removed before declaring a patient safe.
A New Drug Lead Emerges From The Clotting Connection
The coagulation discovery did not stay theoretical for long. A multi-center study co-led by Mayo Clinic and Michigan State University tested tranexamic acid, a drug already used to control bleeding, in patients undergoing liver resection. Patients who received the drug were about three times less likely to develop post-hepatectomy liver failure compared to those given a placebo.
That finding, built directly on the blood-clotting link Starlinger’s team uncovered, gives surgeons a concrete tool rather than just a theory. Instead of only watching and waiting after surgery, doctors may soon have a medication that actively lowers the risk of the liver’s recovery falling short. It is the kind of practical payoff that makes basic science worth the investment.
What This Means For Future Liver Surgery Patients
Doctors already use techniques like portal vein embolization to redirect blood flow and encourage a diseased liver section to shrink while the healthy part grows stronger before surgery even begins. Pairing those pre-surgery strategies with new drug options targeting coagulation could widen the pool of patients eligible for liver operations that once carried too much risk.
Mayo Clinic’s research team, including Starlinger, continues studying the biological switches that separate effective regeneration from failure. For patients facing liver surgery, the message is straightforward: scientists are closing in on why some livers bounce back and others do not, and that knowledge is already translating into safer surgical care.
The liver can regrow itself. But after major surgery, that remarkable ability can be put to the test.
When part of the liver is removed to treat cancer or other conditions, the remaining tissue must regenerate to restore function.
Dr. Patrick Starlinger, a hepatobiliary and… pic.twitter.com/FCXBfkCKaG
— Mayo Clinic (@MayoClinic) October 14, 2026
Few organs give the body a second chance quite like the liver does. Mayo Clinic’s work on coagulation and regeneration shows that even a well-known biological marvel still holds secrets worth chasing, and each discovery brings real, measurable benefits to patients lying on the operating table.
Sources:
youtube.com, newsnetwork.mayoclinic.org, mayoclinic.org, pmc.ncbi.nlm.nih.gov, mayo.edu, pubmed.ncbi.nlm.nih.gov
